Introduction Besides classical cancer treatment, immunotherapy has gained significant attention in recent decades. Immune checkpoint (ICP) blockade therapies (ICBs) using monoclonal antibodies (mAbs) against programmed cell death-1 (PD-1) and its ligand (PD-L1), lymphocyte activating gene-3 (LAG-3) or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) have demonstrated remarkable clinical impact.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile